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Abstract
An 18-year-old Ethiopian woman presented with debilitating back pain and high fever. X-ray
examinations showed diffuse pulmonary tuberculosis and a psoas abscess. After starting rifampicin,
isoniazid, ethambutol and pyrazinamide, acute interstitial nephritis developed that spontaneously
recovered. According to Harrison’s Online rifampicin should have been causative, but the
spontaneous recovery excluded that possibility. The clinical course fit the diagnosis of a paradoxical
response, for which recently risk factors have been described. Thus, a paradoxical response should
be added to the list of causes of interstitial nephritis in tuberculosis patients and in such cases
rifampicin could be continued.
Introduction
Rifampicin, mostly in combination with isoniazid,
ethambutol and pyrazinamide, is the first-line therapy
for tuberculosis. Rifampicin’s most feared side effect is
hepatotoxicity. However, nephrotoxicity such as acute
tubular necrosis and interstitial nephritis (IN) have also
been reported. In case of acute tubular necrosis, rifampi-
cin-dependent antibodies have been found, suggesting a
causal relationship between rifampicin and renal failure
[1]. In acute IN only a temporal relationship is reported
[2, 4]. In spite of the unproven causal relation, Harrison’s
online lists rifampicin as cause of IN [5]. We present a
patient with miliary tuberculosis, who developed IN
during rifampicin, yet spontaneously recovered. Our
observation and recent literature suggest that in case of
hematogenously disseminated tuberculosis, a paradoxical
response (PR) should be added to the list of possible
causes of IN.
Case presentation
An 18-year-old Ethiopian woman was presented with
debilitating back pain, weight loss and high fever. A
month earlier an abscess of her right buttock was surgically
drained. Physical examination revealed an ill-looking
young woman with a temperature of 40.1°C. The abdo-
men was painful at palpation and the liver slightly
enlarged. The chest X-ray was compatible with diffuse
pulmonary tuberculosis. A CT scan of the abdomen
showed a psoas abscess on the left side. Laboratory data
revealed: CRP 191 mg/l, Hb 6.0 mmol/l, lymphocyte
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9/l, creatinine 93 micromol/l, blood urea
nitrogen 3.8 mmol/l and serum albumin 20 g/l. Urinalysis
showed no protein, cells or casts. HIV serology was
negative. Acid-fast bacilli were found in the pus of the
psoas abscess, so the diagnosis of hematogenously
disseminated tuberculosis was established. Treatment
with rifampicin, isoniazid, ethambutol and pyrazinamide
was started. After 6 weeks on this four-drug regimen
laboratory tests were repeated. Serum creatinine had risen
to 272 micromol/l with a simultaneous rise of the
lymphocyte count to 1.5 × 10
9/l. Urinalysis showed
2+ protein, but no cells or casts. Protein excretion was
2.1 g/day. All four drugs were continued, albeit that the
dosage of ethambutol was reduced with 50%. In the ninth
week of treatment a renal biopsy was performed. Light
microscopy revealed normal glomeruli but the intersti-
tium showed a dense mononuclear infiltrate, existing of
lymphocytes, some plasma cells and a few eosinophils.
There were no signs of acute tubular necrosis. A Ziehl-
Neelsen stain was negative for mycobacteria (Figure1). On
immunofluorescence: IgG was negative, IgA was positive
in parts of some tubuli and IgM showed an atypical
staining of the glomeruli. At the time of renal biopsy
serum creatinine was 240 micromol/l and when the result
of the biopsy became available it had decreased to
203 micromol/l. Because of this spontaneous recovery,
all drugs were continued. Seven weeks after the renal
biopsy, serum creatinine had returned to pre-treatment
values. Nine months later treatment was stopped and
the laboratory data were: Hb 8.0 mmol/l, creatinine
88 micromol/l, serum albumen 39 g/l and protein
excretion 0.2 g/day.
Discussion
The introduction of effective anti-tuberculosis treatment
has been accompanied with acute renal failure. In the early
fifties of last century nephrotoxicity of streptomycin, one
of the first aminoglycosides, was causative. When rifampi-
cin became available, acute tubular necrosis was described.
Almost all of the patients had rifampicin-dependent
antibodies against the I-antigen which is present on
erythrocytes and also on tubular epithelial cells. This
I-antigen therefore could be the target through which the
drug leads to acute tubular necrosis [1]. In the nineteen-
seventies, case histories of acute IN were published.
Rifampicin was given for 21 to 71 days and renal biopsies
showed interstitial infiltrates. The drug was stopped and
renal function recovered. Due to this temporal relation-
ship, an immune-mediated or direct nephrotoxicity of
rifampicin was postulated [2–4]. However; such temporal
relationship could also be compatible with a PR.
Paradoxical enlargement of intracranial tuberculomas
during anti-tuberculosis treatment were reported in the
early nineties of last century and called PR [6]. Later, with
the start of highly effective anti-retroviral therapy, PR
became more common in HIV-positive patients with
hematogenously disseminated tuberculosis during anti-
tuberculosis treatment. Recently, even IN in such a patient
has been reported. Two months after the start of the
combination of anti-retroviral and anti-tuberculosis treat-
ment, renal failure developed and renal biopsy revealed
interstitial infiltrates. Assuming PR, rifabutin a rifamycin
not negatively affecting the anti-retroviral therapy was
continued and prednisone was added. Renal function
improved within two weeks [7].
PR is defined as a transient worsening of pre-existing, often
symptomless, lesions during anti-tuberculosis treatment.
The etiology is unknown, although an interaction between
the host's immune response and mycobacterial products
has been suggested. PR occurs more frequently in HIV-
positive patients. Risk factors for developing PR in HIV-
negative patients are: anemia (Hb<6.8 mmol/l), low
serum albumin (< 30g/l) and a low lymphocyte count
(< 0.8 × 10
9/l). Furthermore, during PR a significant rise of
the lymphocyte count (> 0.3 × 10
9/l) is seen [8]. Anti-
tuberculosis treatment during a PR should be continued.
Our patient had hematogenously disseminated tubercu-
losis and abovementioned phenomena. Our hypothesis is
that during the hematogenous spread mycobacteria are
trapped within the kidney and cause IN i.e. PR during anti-
tuberculosis treatment. The fact that the patient received
quadruple therapy for nine weeks, could explain the
absence of mycobacteria in the renal biopsy.
Transient IN during rifampicin treatment in HIV-negative
tuberculosis patients has been described before, but not
Figure 1.
Renal biopsy with a dense infiltrate in the interstitium, existing
of lymphocytes, some plasma cells and a few eosinophils.
No signs of acid-fast bacilli or acute tubular necrosis.
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of pyrazinamide while rifampicin was continued. The
authors postulated pyrazinamide as the cause of the
nephritis [9]. Another patient developed IN while receiv-
ing triple therapy. Rifampicin and isoniazid were stopped
without effect. When ethambutol was stopped as well,
renal function improved. Then rifampicin and isoniazid
were reintroduced without detrimental effect. Thus
ethambutol was considered the culprit [10]. Both patients
however, had hematogenously disseminated tuberculosis
and anemia. So PR seems a more likely explanation.
Unfortunately, the case histories of rifampicin-associated
IN contain insufficient data to draw conclusions about a
possible PR.
Conclusion
HIV-negative tuberculosis patients with well-defined risk
factors may develop IN during anti-tuberculosis therapy.
This nephritis should be considered a PR, thus anti-
tuberculosis drugs could be continued and corticosteroids
eventually added.
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